AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37925960 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA tACS
Number of subjects: 60
Study 37925960 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 60
Study 37925960 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stimulation group
Number of subjects: 60
Study 37926085 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast enhanced magnetic resonance imaging (MRI)
Number of subjects: 7
Study 37926100 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 1281
Study 37926100 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated epirubicin
Number of subjects: 1281
Study 37926100 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 1281
Study 37926100 — intervention group
Group type: COMPARATOR
Intervention: Standard epirubicin
Number of subjects: 1281
Study 37926123 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote skin testing and biophysical testing from birth to monitor skin barrier maturation.
Number of subjects: 128
Study 37926123 — intervention group
Group type: EXPERIMENTAL
Intervention: Common filaggrin risk alleles screening.
Number of subjects: 128
Study 37926123 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of lipid/protein ratio and chymotrypsin-like activity at birth.
Number of subjects: 128
Study 37926123 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepidermal water loss measurement.
Number of subjects: 128
Study 37926224 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 min) + overground gait training (40 min for 5 days)
Number of subjects: 34
Study 37926224 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (30-s stimulation) + overground gait training (40 min for 5 days)
Number of subjects: 34
Study 37926336 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarkers (α-glutathione-S-transferase, albumin, cystatin C) measured at 27, 30, and 34 weeks' postmenstrual age
Number of subjects: 327
Study 37926336 — intervention group
Group type: COMPARATOR
Intervention: Exploratory case-control study
Number of subjects: 327
Study 37926429 — intervention group
Group type: EXPERIMENTAL
Intervention: 90° bend angle stylet
Number of subjects: 98
Study 37926429 — intervention group
Group type: COMPARATOR
Intervention: 70° bend angle stylet
Number of subjects: 98
Study 37926984 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive End-Expiratory Pressure (PEEP)
Number of subjects: 0
Study 37926984 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2
Number of subjects: 0
Study 37927032 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 37927075 — intervention group
Group type: EXPERIMENTAL
Intervention: cPCV7 Coadministered with PCV13 at ages 2, 4, 6, and 12 months
Number of subjects: 512
Study 37927075 — intervention group
Group type: EXPERIMENTAL
Intervention: cPCV7 Separated given at ages 3, 5, 7, and 13 months, 3-5 weeks after PCV13
Number of subjects: 512
Study 37927075 — intervention group
Group type: COMPARATOR
Intervention: PCV13 Control followed by a single supplemental dose of cPCV7 at 13 months
Number of subjects: 512
Study 37927585 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchronic supplementation of a standardised phospholipid carrier-based intervention
Number of subjects: 0
Study 37927936 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus gemcitabine (GnP-NAT), 125 mg/m²
Number of subjects: 61
Study 37928150 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 378
Study 37928150 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NIHSS <20
Number of subjects: 378
Study 37928335 — intervention group
Group type: EXPERIMENTAL
Intervention: Health App for Post-Pandemic Years (HAPPY)
Number of subjects: 814
Study 37928434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell transplantation (MSCT)
Number of subjects: 0
Study 37928434 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miR-320b
Number of subjects: 0
Study 37928473 — intervention group
Group type: EXPERIMENTAL
Intervention: AZVUDINE (FNC)
Number of subjects: 0
Study 37928473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37928549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tixagevimab/Cilgavimab 300 mg IV
Number of subjects: 77
Study 37928549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tixagevimab/Cilgavimab 300 mg IM
Number of subjects: 77
Study 37928549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tixagevimab/Cilgavimab 600 mg IV
Number of subjects: 77
Study 37928549 — intervention group
Group type: EXPERIMENTAL
Intervention: Regdanvimab 40 mg/kg IV
Number of subjects: 77
Study 37928754 — intervention group
Group type: EXPERIMENTAL
Intervention: COMEX program (3-month participation, video-based dialysis chair exercises including aerobic and resistance exercises, educational and motivational components)
Number of subjects: 17
Study 37928754 — intervention group
Group type: EXPERIMENTAL
Intervention: COMEX program
Number of subjects: 17
Study 37928891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bemnifosbuvir (AT-527)
Number of subjects: 0
Study 37928891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37928895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (PC)
Number of subjects: 3
Study 37928895 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus chemotherapy (NC)
Number of subjects: 3
Study 37928920 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-glasses (peripheral visual stimuli embedded in standard eyeglasses)
Number of subjects: 108
Study 37928920 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-glasses
Number of subjects: 108
Study 37928922 — intervention group
Group type: COMPARATOR
Intervention: Metabolomic profiling using liquid chromatography-tandem mass spectrometry to quantify 54 metabolites.
Number of subjects: 499
Study 37928922 — intervention group
Group type: COMPARATOR
Intervention: Subset of 42 biomarkers identified in autistic individuals.
Number of subjects: 499
Study 37928922 — intervention group
Group type: COMPARATOR
Intervention: Hierarchical clustering of biomarkers.
Number of subjects: 499
Study 37928922 — intervention group
Group type: COMPARATOR
Intervention: Metabolic changes associated with clusters.
Number of subjects: 499
Study 37928922 — intervention group
Group type: COMPARATOR
Intervention: Association of autism severity and cognitive impairment with metabolic markers.
Number of subjects: 499
Study 37928925 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention (RP) therapy based on cognitive behavioral treatment (CBT), comprising five to seven 45-min sessions over a period of 5 to 7 weeks.
Number of subjects: 111
Study 37928925 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 111
Study 37928934 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Together for MS (PAT-MS) intervention, a 12-week dyadic behavioural intervention.
Number of subjects: 0
Study 37928934 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition.
Number of subjects: 0
Study 37929584 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 562
Study 37929584 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 562
Study 37929587 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI+OMT
Number of subjects: 700
Study 37929587 — intervention group
Group type: COMPARATOR
Intervention: OMT alone
Number of subjects: 700
Study 37929602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid 180 mg daily
Number of subjects: 13970
Study 37929602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13970
Study 37929602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 13970
Study 37929615 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal carbon dioxide (ETCO2) monitoring during CPR
Number of subjects: 234
Study 37929672 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (target 45 mg)
Number of subjects: 244
Study 37929672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 37929672 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (target 300 mg)
Number of subjects: 244
Study 37929764 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) score >300
Number of subjects: 1931
Study 37929764 — intervention group
Group type: COMPARATOR
Intervention: No calcification
Number of subjects: 1931
Study 37929770 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term home exercise program, details on dosage and duration not specified.
Number of subjects: 0
Study 37929770 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study 37929782 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants rs9939224
Number of subjects: 12031
Study 37929831 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein formula (≥ 2.5 g per 100 kcal)
Number of subjects: 1185
Study 37929831 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein formula
Number of subjects: 1185
Study 37929831 — intervention group
Group type: COMPARATOR
Intervention: Low-protein formula
Number of subjects: 1185
Study 37929840 — intervention group
Group type: COMPARATOR
Intervention: PDE5 inhibitors (PDE5i)
Number of subjects: 411
Study 37929952 — intervention group
Group type: COMPARATOR
Intervention: NUC
Number of subjects: 238
Study 37929952 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg plus NUC
Number of subjects: 238
Study 37930156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib 65 mg daily
Number of subjects: 48
Study 37930156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib (varied doses 5 to 75 mg once daily)
Number of subjects: 48
Study 37930156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Number of subjects: 48
Study 37930231 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexyloctane (PFHO) ophthalmic solution (MIEBO™)
Number of subjects: 0
Study 37930231 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic saline solution
Number of subjects: 0
Study 37930244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose protein (≥ 2.2 g/kg/d)
Number of subjects: 425
Study 37930244 — intervention group
Group type: COMPARATOR
Intervention: Usual-dose protein (≤ 1.2 g/kg/d)
Number of subjects: 425
Study 37930283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog visits
Number of subjects: 26
Study 37930283 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study 37930478 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 60
Study 37930478 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 37930669 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (2 mg/d or 3 mg/d)
Number of subjects: 345
Study 37930669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 37930692 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT-ILE (50 hours over 2 weeks)
Number of subjects: 50
Study 37930692 — intervention group
Group type: COMPARATOR
Intervention: Usual motor activity (control group)
Number of subjects: 50
Study 37930756 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 10
Study 37930756 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study 37930767 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based couple intervention (COMPANION) consisting of psychoeducation, mindfulness, and cognitive-behavioral exercises, supervised remotely by a trained therapist for 9 sessions.
Number of subjects: 0
Study 37930767 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based couple intervention (COMPANION)
Number of subjects: 0
Study 37930773 — intervention group
Group type: EXPERIMENTAL
Intervention: Information guide for adult kidney transplant patients
Number of subjects: 5
Study 37930776 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral EVOQUE transcatheter TV replacement
Number of subjects: 176
Study 37930781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen voice-based coach delivering 8 problem-solving treatment sessions
Number of subjects: 42
Study 37930786 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated messaging for weight loss (6-12 months)
Number of subjects: 40
Study 37930786 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 40
Study 37930792 — intervention group
Group type: EXPERIMENTAL
Intervention: Later scheduled start time
Number of subjects: 223
Study 37930792 — intervention group
Group type: EXPERIMENTAL
Intervention: Later schedule end time
Number of subjects: 223
Study 37930792 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities extending beyond 10 pm
Number of subjects: 223
Study 37930792 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daily documented total activity time
Number of subjects: 223
Study 37931065 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Single-Session Interventions (SSIs)
Number of subjects: 0
Study 37931065 — intervention group
Group type: COMPARATOR
Intervention: Placebo Control
Number of subjects: 0
Study 37931185 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor cell count-driven therapy
Number of subjects: 0
Study 37931185 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 37931304 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy - Taking it Further (MBCT-TiF)
Number of subjects: 164
Study 37931304 — intervention group
Group type: COMPARATOR
Intervention: Ongoing Mindfulness Practice (OMP)
Number of subjects: 164
Study 37931334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha Yoga intervention for 8 weeks
Number of subjects: 98
Study 37931334 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 98
Study 37931372 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal dietary cluster 1 (plant protein and fibers)
Number of subjects: 60
Study 37931372 — intervention group
Group type: COMPARATOR
Intervention: Maternal dietary cluster 2 (animal protein)
Number of subjects: 60
Study 37931372 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-378 and 320 family miRNAs
Number of subjects: 60
Study 37931445 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and etoposide (CP/ET)
Number of subjects: 0
Study 37931445 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin and etoposide (CP/ET)
Number of subjects: 0
Study 37931480 — intervention group
Group type: EXPERIMENTAL
Intervention: eIMPACT intervention (internet cognitive-behavioral therapy [CBT], telephonic CBT, and select antidepressant medications)
Number of subjects: 216
Study 37931480 — intervention group
Group type: COMPARATOR
Intervention: usual primary care
Number of subjects: 216
Study 37931481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vertebrobasilar ischemia (VBI)
Number of subjects: 107
Study 37931481 — intervention group
Group type: COMPARATOR
Intervention: Controls (29 age- and sex-matched healthy persons)
Number of subjects: 107
Study 37931629 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan combined with dapagliflozin
Number of subjects: 449
Study 37931629 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 449
Study 37931632 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with pembrolizumab (n=222)
Number of subjects: 440
Study 37931632 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (n=218)
Number of subjects: 440
Study 37931634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparsentan (400 mg oral once daily)
Number of subjects: 404
Study 37931634 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan (300 mg oral once daily)
Number of subjects: 404
Study 37931634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 404
Study 37931634 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 404
Study 37931749 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Low-Carbohydrate (HLC) diet
Number of subjects: 448
Study 37931749 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Low-Fat (HLF) diet
Number of subjects: 448
Study 37931749 — intervention group
Group type: COMPARATOR
Intervention: High Quality (HQ) and High Adherence (HA) subgroups
Number of subjects: 448
Study 37931749 — intervention group
Group type: COMPARATOR
Intervention: Low Quality (LQ) and Low Adherence (LA) subgroups
Number of subjects: 448
Study 37931967 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO digital health application combined with proactive follow-up by nurses
Number of subjects: 205
Study 37931967 — intervention group
Group type: COMPARATOR
Intervention: Usual healthcare and a list of breast cancer information sources
Number of subjects: 205
Study 37931968 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent drive for thinness
Number of subjects: 887
Study 37931968 — intervention group
Group type: COMPARATOR
Intervention: Persistently high weight trajectory
Number of subjects: 887
Study 37932009 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib (100 mg, one or two times a day)
Number of subjects: 0
Study 37932009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37932009 — intervention group
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Number of subjects: 0
Study 37932258 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1467335 1 mg
Number of subjects: 81
Study 37932258 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1467335 3 mg
Number of subjects: 81
Study 37932258 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1467335 6 mg
Number of subjects: 81
Study 37932258 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1467335 10 mg
Number of subjects: 81
Study 37932258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 37932258 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 1467335 (≥3 mg)
Number of subjects: 81
Study 37932443 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan dosage adjusted based on UGT1A1 polymorphisms, specifically 370 mg/m² for *1/*1 genotype.
Number of subjects: 34
Study 37932443 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan dosage adjusted based on UGT1A1 polymorphisms.
Number of subjects: 34
Study 37932443 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of irinotecan (180 mg/m²).
Number of subjects: 34
Study 37932493 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-education intervention with booster training sessions
Number of subjects: 560
Study 37932493 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster training sessions
Number of subjects: 560
Study 37932493 — intervention group
Group type: COMPARATOR
Intervention: Control networks
Number of subjects: 560
Study 37932539 — intervention group
Group type: EXPERIMENTAL
Intervention: how
Number of subjects: 3665
Study 37932539 — intervention group
Group type: EXPERIMENTAL
Intervention: why
Number of subjects: 3665
Study 37932539 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 3665
Study 37932589 — intervention group
Group type: EXPERIMENTAL
Intervention: mesoglycan 50 mg bid
Number of subjects: 650
Study 37932589 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 650
Study 37932609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 296 MBq PET/CT
Number of subjects: 712
Study 37932648 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative plasma transforming growth factor beta 1 (TGF-β1) concentration
Number of subjects: 80
Study 37932649 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia (RA)
Number of subjects: 76
Study 37932649 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 76
Study 37932650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation-derived mean arterial pressure targets ranging from 55 to 100 mm Hg.
Number of subjects: 42
Study 37932730 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 1: Messages sent through the health system patient portal
Number of subjects: 0
Study 37932730 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 2: Text message outreach to non-responders from Step 1
Number of subjects: 0
Study 37932730 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 3: Clinician contact using a 'pend and send' tool in the EHR for non-responders from Step 2
Number of subjects: 0
Study 37932739 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg suramin
Number of subjects: 52
Study 37932739 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg suramin
Number of subjects: 52
Study 37932739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 37932787 — intervention group
Group type: EXPERIMENTAL
Intervention: POINCARE-2 strategy (daily weighing over 14 days, restriction of fluid intake, administration of diuretics, and/or ultrafiltration)
Number of subjects: 1361
Study 37932787 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1361
Study 37932812 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion (500-mL saline infusion)
Number of subjects: 69
Study 37932812 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine dose increase
Number of subjects: 69
Study 37932848 — intervention group
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET/MRI
Number of subjects: 40
Study 37932961 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Aβ42/Aβ40
Number of subjects: 0
Study 37932961 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylated variant p-tau181 ratio (p-tau181/np-tau181)
Number of subjects: 0
Study 37932961 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylated variant p-tau217 ratio (p-tau217/np-tau217)
Number of subjects: 0
Study 37932961 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Predicted Centiloid (PPC) model including p-tau217/np-tau217, Aβ42/Aβ40, age, and apolipoprotein E
Number of subjects: 0
Study 37933185 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth platform with automated text notifications on days 1, 3, 5, and 7
Number of subjects: 1525